Foresight Diagnostics is a cancer diagnostics company that develops ultra-sensitive ctDNA assays through the combination of precision genomics and bioinformatics. Our proprietary PhasED-Seq technology tracks patient- and tumor-specific phased variants to detect residual disease down to the parts per million, enabling early and accurate relapse detection at the end of treatment. Our MRD platform, Foresight CLARITY, is available across multiple indications, including lymphoma, lung, and breast cancer.
Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive (with a detection limit below 0.0001% or one part-per-million) than existing tests. The improved sensitivity of the Foresight MRD assays can provide clinically actionable information to physicians and biopharmaceutical companies.